Germantown, MD – According to filings with the U.S. Securities and Exchange Commission, Orgenesis is raising $9,240,000.00 in new funding. Sources indicate as part of senior management President and Chief Executive Officer, Vered Caplan played a key role in securing the recent investment and it will aid in aggressively expanding the company, as well as broaden and accelerate product development.

About Orgenesis

Orgenesis is a vertically-integrated biopharmaceutical company with unique expertise and experience in cell therapy development and manufacturing. Orgenesis is developing its own propriety cell therapies. Through its subsidiary Orgenesis Ltd., Orgenesis is a pioneer in the process of Transdifferentiation (or cell reprograming), whereby an adult cell is converted into another type of cell, with its distinct phenotype and function. Orgenesis has utilized its proprietary technology/processes to successfully reprogram human liver cells into glucose-responsive, fully functional, insulin producing cells.

To learn more about Orgenesis, visit http://www.orgenesis.com/

Contact:
Vered Caplan, President and Chief Executive Officer
480-659-6404
vered.c@orgenesis.com
https://www.linkedin.com/in/vered-caplan-4366928/

SOURCE: http://www.intelligence360.io
Copyright (c) 2020 SI360 Inc. All rights reserved